Risperdal Lawsuits

07/22/2014

Risperdal Lawsuits Will Not Include Claims for Punitive Damages

Risperdal Lawsuit Bars Claims for Punitive Damages

Audet & Partners, LLP reports that a judge in Pennsylvania overseeing hundreds of Risperdal lawsuits has ruled that the plaintiffs in these lawsuits will be barred under New Jersey law from asserting claims for punitive damages.  This ruling, that upheld an earlier ruling in May 2014, in no way affects claims for compensatory damages to cover medical expenses, reconstructive surgery, and the costs of other physical problems caused by Risperdal. As we have previously reported, Janssen Pharmaceuticals, a division of Johnson &... Read More
07/10/2014

Risperdal Lawsuit Update: Court Conference Scheduled for July 15, 2014

Risperdal Lawsuit Bars Claims for Punitive Damages

Audet & Partners, LLP reports that hundreds of Risperdal lawsuits now pending in Pennsylvania state courts are moving forward.  A conference is next scheduled for July 15, 2014, at which the parties will further discuss the further of the Risperdal litigation. In the Philadelphia Court of Common Pleas (Risperdal Litigation, Case Number 100300296), more than 500 Risperdal lawsuits have been joined in multidistrict litigation (MDL) to facilitate factual discovery and other litigation procedures common to most of the pending lawsuits. Audet &... Read More
07/01/2014

Whistleblower Lawsuit Against Omnicare Nets $124 Million for Federal Government

Whistleblower Award

The Federal government has accepted a $124 million settlement from Omnicare to resolve several claims initiated by company employees who reported illegal kickbacks and other improprieties to regulators.  Omnicare is the largest provider of pharmaceuticals and pharmacy services to nursing homes in the United States. The whistleblower lawsuits, brought under the federal False Claims Act, challenged Omnicare's practice of offering below-cost contracts to supply pharmaceuticals and pharmacy services to skilled nursing facilities to secure provider contracts with these facilities.  According to... Read More
06/18/2014

Risperdal Off-Label Prescriptions May Expose Johnson & Johnson to Punitive Damages

Risperdal Punitive Damages

Plaintiffs in consolidated Risperdal lawsuits now pending in Pennsylvania have argued that a New Jersey statute barring punitive damages in lawsuits brought involving FDA-approved drugs does not apply when the injuries alleged result from off-label or uses unapproved by the FDA. Janssen Pharmaceuticals, Inc., the division of Johnson & Johnson that manufactured and distributed Risperdal, had argued that insofar as the antipsychotic medication had been approved by the FDA, the plaintiffs in hundreds of lawsuits coordinated in Pennsylvania could not prevail... Read More
06/18/2014

Risperdal Off-Label Prescriptions May Expose Johnson & Johnson to Punitive Damages

Risperdal Punitive Damages

Plaintiffs in consolidated Risperdal lawsuits now pending in Pennsylvania have argued that a New Jersey statute barring punitive damages in lawsuits brought involving FDA-approved drugs does not apply when the injuries alleged result from off-label or uses unapproved by the FDA. Janssen Pharmaceuticals, Inc., the division of Johnson & Johnson that manufactured and distributed Risperdal, had argued that insofar as the antipsychotic medication had been approved by the FDA, the plaintiffs in hundreds of lawsuits coordinated in Pennsylvania could not prevail... Read More
05/27/2014

Risperdal Lawsuits Time Barred, Argues Johnson & Johnson

Risperdal Lawsuit Bars Claims for Punitive Damages

Janssen Pharmaceuticals, a division of Johnson & Johnson  that manufactured and marketed the antipsychotic drug Risperdal to adolescent males, asked a Pennsylvania court in a Motion for Summary Judgment dated May 19, 2014, to hold that hundreds of personal injury claims connected to Risperdal administration should be time barred by the applicable statute of limitations.  In its Motion, Janssen has argued that plaintiffs have filed injury claims years, and in some cases, decades after developing a condition called gynecomastia, and... Read More
05/07/2014

Risperdal Birth Defect Lawsuit Update

risperdal-litigtaion-update

Audet & Partners, LLP reports that consolidated Risperdal birth defect lawsuits now being heard in Philadelphia Court of Common Pleas (Risperdal Litigation, Case No. 100300296) are moving forward.  Issues related to the litigation against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, will be discussed in court on Tuesday, May 13, 2014 at 10:30 a.m. To learn more about pending Risperdal lawsuits, contact Audet & Partners, LLP by calling (800) 965-1461, or by completing and submitting our confidential inquiry form on... Read More
05/02/2014

Risperdal Class Action FAQs

Risperdal Lawsuit Update

Audet and Partners, LLP is now representing several males who have been diagnosed with Gynecomastia after having taken the antipsychotic drug Risperdal.  If you have suffered this or a similar injury, you may be wondering whether you may have a valid claim for damages. The FAQs below are intended to better help you understand and assess how you might proceed in bringing a Risperdal lawsuit. (1) What is the basis for the current Risperdal lawsuits against Johnson & Johnson? For over a decade,... Read More
04/16/2014

Whistleblower Lawsuits On The Rise

Whistleblower Award

Whistleblower claims, or "qui tam" lawsuits, brought under the federal False Claims Act, increased to 753 in 2013, an increase of almost 20% over the previous year.*  These claims resulted in aggregate net recoveries to the federal government of $3.8 billion last year.  For the past four years, whistleblower lawsuits have produced recoveries to the federal government exceeding an aggregate amount of $3 billion. What is driving the rise in whistleblower lawsuits under the False Claims Act?  False claims involving healthcare... Read More
04/03/2014

Risperdal Gynecomastia Link Detailed in New Study

Ripserdal Gynecomastia Lawsuits

New research presented at the American Association for Geriatric Psychiatry (AAGP) 2014 Annual Meeting appears to substantiate the link between Johnson & Johnson’s drug Risperdal and gynecomastia, the development of breasts in men and young boys in a condition being referred to as Risperdal Gynecomastia. The research was presented by Dr. Mahyar Etminan, a prominent pharmaceopidemiologist and lead researcher at the University of British Columbia.  The team of researchers studied tens of thousands of patients to examine side effects of the... Read More
03/25/2014

Risperdal Lawsuit $1.2 Billion Verdict Overturned by Arkansas Supreme Court

Risperdal Lawsuit News

On March 20, 2014, the Arkansas Supreme Court overturned a trial court award of $1.2 billion to the State of Arkansas against Johnson & Johnson, and its Janssen Pharmaceuticals, Inc. division based on the company's marketing of the antipsychotic frog Risperdal.  This Arkansas lawsuit had been brought by the Arkansas Attorney General and relied on a provision of Arkansas state law governing Medicaid fraud as a basis to challenge the marketing of Risperdal in Arkansas which allegedly included misleading claims... Read More
03/12/2014

Risperdal Lawsuit Settlement Costs Johnson & Johnson $5.9 Million

Risperdal Lawsuits

Janssen Pharmaceutical, Inc., the division of Johnson & Johnson that developed and marketed the Risperdal antipsychotic medication, has settled a Risperdal lawsuit brought by the State of Montana for $5.9 million.  The Attorney General of Montana had initiated a lawsuit against the manufacturer in 2008 alleging that the company promoted the drug as safe despite having knowledge of a range of dangerous side effects, including diabetes. The settlement terms require Johnson & Johnson to cease any misleading marketing of Risperdal, and... Read More